APLS - Company ID 0001492422
The table below shows Apellis Pharmaceuticals, Inc.'s balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $466.23M | $411.29M | $351.19M | $551.80M | $640.19M | $565.78M |
| Short-term investments | - | - | - | $60.36M | $60.36M | $311.87M |
| Receivables | $366.22M | $264.93M | $206.44M | $7.73M | $10.10M | - |
| Inventory | $142.56M | $81.40M | $146.36M | $85.71M | $16.29M | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $1.01B |
| $788.95M |
| $766.33M |
| $719.52M |
| $824.05M |
| $917.19M |
| Property, plant & equipment | $1.71M | $2.95M | $4.34M | $6.15M | $6.18M | $6.80M |
| Goodwill | - | - | - | - | - | - |
| Total assets | $1.08B | $885.05M | $788.73M | $760.22M | $881.76M | $960.57M |
| Accounts payable | $56.80M | $38.57M | $37.52M | $37.34M | $16.91M | $8.48M |
| Total current liabilities | $323.60M | $185.51M | $247.59M | $167.61M | $131.85M | $128.33M |
| Long-term debt | - | - | $93.03M | $92.74M | - | - |
| Total liabilities | $705.11M | $656.51M | $594.21M | $590.35M | $683.10M | $756.01M |
| Retained earnings | -$3.01B | -$3.04B | -$2.84B | -$2.31B | -$1.66B | -$926.35M |
| Total equity | $370.15M | $228.54M | $194.52M | $169.87M | $198.66M | $204.56M |